A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery (FONDACAST)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00843492
First received: December 11, 2008
Last updated: February 6, 2014
Last verified: June 2012
  Purpose

The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by ultrasound, and pulmonary embolism (blood clots that migrate to the lungs) in patients with leg injuries below the knee that require a cast or other type of immobilization but not surgery.


Condition Intervention Phase
Thrombosis, Venous
Drug: Fondaparinux sodium
Drug: Nadroparin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Multicentre, Randomized, Open-label Study to Evaluate the Efficacy andSafety of Fondaparinux Versus Low Molecular Weight Heparin(Nadroparin) in Patients Requiring Rigid or Semi-rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isolated Non-surgical Below-Knee Injury

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of Participants With Venous Thromboembolism (VTE) or Death up to the Time of Complete Mobilization [ Time Frame: Day 1 to complete mobilization plus 2 days (average of 35.9 study days) ] [ Designated as safety issue: No ]
    VTE is defined as asymptomatic deep vein thrombosis (DVT: the formation of a blood clot in a deep vein) detected by systematic compression ultrasonography, symptomatic DVT, or symptomatic fatal or non-fatal pulmonary embolism (PE). An embolism is a clot in the blood that forms and blocks a blood vessel. A pulmonary embolism is a blood clot that has travelled from elsewhere in the body through the blood stream to block the main artery of the lung or one of its branches. All venous thromboembolic events and deaths were adjudicated by the independent Central Adjudication Committee (CAC).


Secondary Outcome Measures:
  • Number of Participants With Any Adjudicated Components of VTE, Asymptomatic DVT, Symptomatic DVT, Symptomatic PE, and Death [ Time Frame: Day 1 to complete mobilization plus 2 days (average of 35.7 study days) ] [ Designated as safety issue: No ]
    All components of the primary endpoint were considered separately: any VTE; symptomatic (providing no evidence of disease existence) DVT (the formation of a blood clot in a deep vein) detected by systematic compression ultrasonography; symptomatic(providing evidence of disease existence) DVT; symptomatic PE (blood clot that has travelled from elsewhere in the body through the blood stream to block the main artery of the lung of one of its branches); and death.

  • Number of Participants With Confirmed VTE and Death up to the Final Visit or Contact [ Time Frame: Day 1 to 5 weeks (plus or minus 1 week) after complete mobilization (average of 67.8 study days) ] [ Designated as safety issue: No ]
    The number of participants with VTE (defined as asymptomatic deep vein thrombosis [DVT: the formation of a blood clot in a deep vein] detected by systematic compression ultrasonography, symptomatic DVT, or symptomatic fatal or non-fatal pulmonary embolism [PE]) and death was assessed. An embolism is a clot in the blood that forms and blocks a blood vessel. A PE is a blood clot that has travelled from elsewhere in the body through the blood stream to block the main artery of the lung or one of its branches.

  • Number of Participants With Major Bleeding From Day 1 to Complete Mobilization and From Day 1 up to the Final Visit or Contact [ Time Frame: Day 1 to complete mobilization plus 4 days (average of 37.7 study days); Day 1 up to final visit or contact (average of 66.3 study days) ] [ Designated as safety issue: No ]
    Major bleeding is defined as bleeding that results in a fatality, symptomatic bleeding in a critical area or organ, bleeding causing a fall in hemoglobin level of 20 grams/liter (1.24 millimoles/liter) or more compared with the pre-randomization hemoglobin level, or bleeding that leads to a transfusion of two or more units of whole blood or red blood cells. All episodes of bleeding were adjudicated by an independent CAC. The committee members were unaware of the participants' treatment assignment.

  • Number of Participants With Clinically Relevant Non-major Bleeding From Day 1 to Complete Mobilization and From Day 1 up to the Final Visit or Contact [ Time Frame: Day 1 to complete mobilization plus 4 days (average of 37.7 study days); Day 1 up to final visit or contact (average of 66.3 study days) ] [ Designated as safety issue: No ]
    Clinically relevant non-major bleeding that does not qualify as major is defined as bleeding leading to treatment discontinuation, and/or epistaxis (bleeding through the nose) that lasts for more than 5 minutes or necessitates intervention (e.g., packing), spontaneous macroscopic haematuria (blood in urine), gastrointestinal haemorrhage, haemoptysis (coughing up blood), or subcutaneous haematoma (localized collection of blood) > 100 centimeters squared. All episodes of bleeding were adjudicated by an independent CAC. The committee members were unaware of the participants' treatment assignment.

  • Number of Participants With Minor Bleeding From Day 1 to Complete Mobilization and From Day 1 up to the Final Visit or Contact [ Time Frame: Day 1 to complete mobilization plus 4 days (average of 37.7 study days); Day 1 up to final visit or contact (average of 66.3 study days) ] [ Designated as safety issue: No ]
    Minor bleeding is defined as clinically overt bleeding events that do not meet the criteria for major or clinically relevant non-major bleeding. All episodes of bleeding were adjudicated by an independent CAC. The committee members were unaware of the participants' treatment assignment.

  • Participants With Any Incidence of Any Bleeding Event as Adjudicated by a CAC) From Day 1 to Complete Mobilization and From Day 1 up to the Final Visit or Contact [ Time Frame: Day 1 to complete mobilization plus 4 days (average of 37.7 study days); Day 1 up to final visit or contact (average of 66.3 study days) ] [ Designated as safety issue: No ]
    All episodes of bleeding, except minor bruising, skin hematomas not greater than 5 centimeters in diameter, self-limited epistaxis (bleeding through the nose), and self-limited gingival (gum) bleeding, were adjudicated by an independent CAC. The committee members were unaware of the participants' treatment assignment.


Enrollment: 1351
Study Start Date: December 2008
Study Completion Date: June 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nadroparin
After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
Drug: Nadroparin
After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
Experimental: Fondaparinux
After randomization (Day 1), subjects will receive subcutaneously, once daily, fondaparinux 2.5 mg (1.5 mg in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
Drug: Fondaparinux sodium
After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg [0.5mL] (1.5 mg [0.3mL] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.

Detailed Description:

The study is designed to evaluate the efficacy and safety of fondaparinux sodium 2.5 mg (1.5 mg in patients with a creatinine clearance between 30 and 50 mL/min) once daily versus Low-Molecular Weight Heparin (nadroparin 2850 anti-Xa IU, 0.3 mL, once daily), with respect to the occurrence of venous thromboembolism, death and bleeding complications in patients requiring rigid or semi-rigid immobilization for at least 21 days and up to 45 days because of isolated nonsurgical below-knee injury. Treatment will be continued up to complete mobilization, e.g. plaster cast or brace removal, for a maximum of 45 days. The study will be a European, multicentre, randomized, open-label, controlled, two-parallel-group, phase III study in 1350 male and female patients 18 years of age or older, presenting with at least one additional major risk factor for VTE. After randomization (Day 1), subjects will receive subcutaneously, once daily, either fondaparinux or nadroparin up to complete mobilization. After cast or brace removal, a systematic, bilateral compression ultrasound will be done in all patients. Patients will be contacted five weeks (± one week) after complete mobilization. All suspected venous thromboembolic events, including asymptomatic deep vein thrombosis, all deaths, and all bleeding events (with the exception of certain types of minor bleeding events defined in the protocol) will be reviewed by an independent adjudication committee blind to treatment assignment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Requiring rigid or semi-rigid immobilization (e.g. with a plaster cast or brace) for at least 21 days and up to 45 days because of isolated non-surgical below-knee injury
  • With a no weight-bearing recommendation at the time of inclusion (partial weight bearing is permitted e.g. crutches, walking cast, relief shoes),
  • Presenting at least one of the following risk factors for venous thromboembolism: below-knee fracture or Achilles tendon rupture, age ≥40 years, body mass index > 30 kg/m2, oestrogen-containing hormonal replacement therapy or oral contraception, active cancer (treatment ongoing or stopped for less than one year), history of VTE, congenital or acquired hypercoagulable state,
  • Requiring thromboprophylaxis according to the Investigator's judgement up to complete mobilization (corresponding to cast or brace removal)
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Delay between injury and randomization greater than two days,
  • Treatment with antithrombotic or anticoagulant therapy, including low-dose anticoagulation, for more than 2 days prior to randomization,
  • Anticoagulant therapy required or likely to be required during the study period for another reason (e.g. planned surgery justifying pharmacological thromboprophylaxis, curative dose for treatment of VTE, etc.)
  • Known hypersensitivity to fondaparinux or nadroparin or their excipient,
  • Known history of heparin-induced thrombocytopenia,
  • Women of childbearing potential not using a reliable contraceptive method throughout the study period,
  • Women pregnant or breast-feeding during the study period.
  • Active, clinically significant bleeding,
  • Clinically significant bleeding within the past six months,
  • Major surgery within the previous three months,
  • Intraocular (other than cataract), spinal, and/or brain surgery within the previous twelve months,
  • Haemorrhagic stroke within the previous twelve months,
  • Severe head injury within the previous three months,
  • Documented congenital or acquired bleeding tendency/disorder(s),
  • Previous (within 12 months) or active or currently treated peptic ulcer disease,
  • Uncontrolled arterial hypertension (systolic blood pressure over 180 mm Hg or diastolic blood pressure over 110 mm Hg),
  • Treatment with more than one antiplatelet agents (e.g. clopidogrel and aspirin) at any dose,
  • Need for chronic aspirin at doses≥ 325 mg or chronic NSAIDs,
  • Bacterial endocarditis,
  • Severe hepatic impairment,
  • Calculated creatinine clearance < 30 mL/min,
  • Thrombocytopenia ( <100x10_9/L)
  • Body weight < 50 kg.
  • Any condition that could prevent the patient from providing written informed consent or from adhering to study treatment,
  • Life expectancy under six months,
  • Participation in any study using an investigational drug during the previous three months,
  • Patient in whom V3 is unlikely to be feasible (e.g. patient moving house),
  • In France, a subject will not be eligible for inclusion in this study if not either affiliated to or a beneficiary of a social security system. This is an additional exclusion criterion only applying to subjects enrolled in France.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00843492

  Hide Study Locations
Locations
France
GSK Investigational Site
Agen Cedex 9, France, 47923
GSK Investigational Site
Angers, France, 49100
GSK Investigational Site
Antony Cedex, France, 92166
GSK Investigational Site
Argenteuil Cedex, France, 95107
GSK Investigational Site
Beauvais Cedex, France, 60021
GSK Investigational Site
Bobigny, France, 93009
GSK Investigational Site
Brest Cedex, France, 29609
GSK Investigational Site
Cergy Pontoise, France, 95303
GSK Investigational Site
Clermont Ferrand, France, 63000
GSK Investigational Site
Colmar Cedex, France, 68024
GSK Investigational Site
Créteil Cedex, France, 94010
GSK Investigational Site
Grenoble Cedex 9, France, 38043
GSK Investigational Site
Lille Cedex, France, 59037
GSK Investigational Site
Lyon, France, 69275
GSK Investigational Site
Lyon Cedex 03, France, 69437
GSK Investigational Site
Lyon Cedex 07, France, 69365
GSK Investigational Site
Mougins, France, 06250
GSK Investigational Site
Nantes, France, 44093
GSK Investigational Site
Orthez Cedex, France, 64301
GSK Investigational Site
Paris, France, 75015
GSK Investigational Site
Paris Cedex 12, France, 75571
GSK Investigational Site
Paris Cedex 13, France, 75651
GSK Investigational Site
Paris Cedex 14, France, 75679
GSK Investigational Site
Paris Cedex 4, France, 75181
GSK Investigational Site
Pringy Cedex, France, 74374
GSK Investigational Site
Rennes cedex 9, France, 35033
GSK Investigational Site
Roanne, France, 42300
GSK Investigational Site
Rouen Cedex, France, 76031
GSK Investigational Site
Saint Pierre cedex, France, 97448
GSK Investigational Site
Sainte Colombe Les Vienne, France, 69560
GSK Investigational Site
Saintes, France, 17108
GSK Investigational Site
Toulouse, France, 31059
GSK Investigational Site
Valenciennes, France, 59300
Germany
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69120
GSK Investigational Site
Erlangen, Bayern, Germany, 91054
GSK Investigational Site
Muenchen, Bayern, Germany, 80339
GSK Investigational Site
Muenchen, Bayern, Germany, 80335
GSK Investigational Site
Wiesbaden, Hessen, Germany, 65191
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Gevelsberg, Nordrhein-Westfalen, Germany, 58285
GSK Investigational Site
Moers, Nordrhein-Westfalen, Germany, 47441
GSK Investigational Site
Zerbst, Sachsen-Anhalt, Germany, 39261
GSK Investigational Site
Dresden, Sachsen, Germany, 01187
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
GSK Investigational Site
Schmiedeberg, Sachsen, Germany, 01762
GSK Investigational Site
Zwickau, Sachsen, Germany, 08060
GSK Investigational Site
Luebeck, Schleswig-Holstein, Germany, 23538
GSK Investigational Site
Altenburg, Thueringen, Germany, 04600
GSK Investigational Site
Berlin, Germany, 12627
GSK Investigational Site
Berlin, Germany, 10559
GSK Investigational Site
Berlin, Germany, 13353
GSK Investigational Site
Hamburg, Germany, 20246
GSK Investigational Site
Hamburg, Germany, 22415
Italy
GSK Investigational Site
Bologna, Emilia-Romagna, Italy, 40136
GSK Investigational Site
Udine, Friuli-Venezia-Giulia, Italy, 33100
GSK Investigational Site
Latina, Lazio, Italy, 04100
GSK Investigational Site
Roma, Lazio, Italy, 00141
GSK Investigational Site
Genova, Liguria, Italy, 16132
GSK Investigational Site
Bergamo, Lombardia, Italy, 24128
GSK Investigational Site
Milano, Lombardia, Italy, 20161
GSK Investigational Site
Orbassano (TO), Piemonte, Italy, 10043
GSK Investigational Site
Catania, Sicilia, Italy, 95126
GSK Investigational Site
Siena, Toscana, Italy, 53100
GSK Investigational Site
Conegliano (TV), Veneto, Italy, 31015
GSK Investigational Site
Padova, Veneto, Italy, 35128
Netherlands
GSK Investigational Site
Amersfoort, Netherlands, 3818 ES
GSK Investigational Site
Eindhoven, Netherlands, 5623 EJ
GSK Investigational Site
Maastricht, Netherlands, 6229 HX
GSK Investigational Site
Sittard-geleen, Netherlands, 6162 BG
GSK Investigational Site
Utrecht, Netherlands, 3582 KE
GSK Investigational Site
Venlo, Netherlands, 5912 BL
Russian Federation
GSK Investigational Site
Barnaul, Russian Federation, 656024
GSK Investigational Site
Ekaterinburg, Russian Federation, 620039
GSK Investigational Site
Ekaterinburg, Russian Federation, 620102
GSK Investigational Site
Irkutsk, Russian Federation, 664003
GSK Investigational Site
Kemerovo, Russian Federation, 650002
GSK Investigational Site
Kursk, Russian Federation, 305035
GSK Investigational Site
Moscow, Russian Federation, 125299
GSK Investigational Site
Novosibirsk, Russian Federation, 630117
GSK Investigational Site
Perm, Russian Federation, 614036
GSK Investigational Site
Ryazan, Russian Federation, 390026
GSK Investigational Site
Saint-Petersburg, Russian Federation, 198260
GSK Investigational Site
Samara, Russian Federation, 443095
GSK Investigational Site
Samara, Russian Federation, 443010
GSK Investigational Site
St. Petersburgh, Russian Federation, 192242
GSK Investigational Site
Stavropol, Russian Federation, 355030
GSK Investigational Site
Tomsk, Russian Federation, 634063
GSK Investigational Site
Tumen, Russian Federation, 625023
GSK Investigational Site
Tver, Russian Federation, 170036
GSK Investigational Site
Ufa, Russian Federation, 450000
GSK Investigational Site
Yaroslavl, Russian Federation, 150003
GSK Investigational Site
Yaroslavl, Russian Federation, 150023
Spain
GSK Investigational Site
Aravaca, Spain, 28023
GSK Investigational Site
Avilés/Asturias, Spain, 33400
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Barcelona, Spain, 08006
GSK Investigational Site
Castellón, Spain, 12004
GSK Investigational Site
Cordoba, Spain, 14004
GSK Investigational Site
Don Benito/Badajoz, Spain, 06400
GSK Investigational Site
Ferrol. La Coruña, Spain, 15405
GSK Investigational Site
Getafe/Madrid, Spain, 28905
GSK Investigational Site
Jaén, Spain, 23007
GSK Investigational Site
La Coruña, Spain, 15006
GSK Investigational Site
Linares, Spain, 23700
GSK Investigational Site
Lugo, Spain, 27004
GSK Investigational Site
Madrid, Spain, 28040
GSK Investigational Site
Madrid, Spain, 28041
GSK Investigational Site
Madrid, Spain, 28034
GSK Investigational Site
Madrid, Spain, 28006
GSK Investigational Site
Majadahonda/Madrid, Spain, 28220
GSK Investigational Site
Mondragón - Guipúzcoa, Spain, 20500
GSK Investigational Site
Ourense, Spain, 32005
GSK Investigational Site
Palencia, Spain, 340014
GSK Investigational Site
Palma de Mallorca, Spain, 07010
GSK Investigational Site
Pozoblanco/Córdoba, Spain, 14400
GSK Investigational Site
San Sebastián de los Reyes/Madrid, Spain
GSK Investigational Site
Santiago de Compostela, Spain, 15706
GSK Investigational Site
Sevilla, Spain, 41071
GSK Investigational Site
Torrelodones/Madrid, Spain, 28250
GSK Investigational Site
Torrevieja, Spain, 03184
GSK Investigational Site
Valdemoro/Madrid, Spain, 28340
GSK Investigational Site
Vigo/Pontevedra, Spain, 36200
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00843492     History of Changes
Other Study ID Numbers: 109350
Study First Received: December 11, 2008
Results First Received: May 24, 2012
Last Updated: February 6, 2014
Health Authority: Spain: Agencia Española del Medicamento y Productos Sanitarios
Italy: Comitato Etico della ASL Città di Milano
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte
France: Agence Française de Sécurité Sanitaire des Produits de Santé
Netherlands: De Centrale Commissie Mensgebonden Onderzoek

Keywords provided by GlaxoSmithKline:
deep vein thrombosis
immobilization
nadroparin
isolated lower-extremity injuries distal to the knee
plaster cast
non-surgical leg injury
venous thromboembolism
bleeding events
fondaparinux

Additional relevant MeSH terms:
Knee Injuries
Thrombosis
Venous Thrombosis
Cardiovascular Diseases
Embolism and Thrombosis
Leg Injuries
Vascular Diseases
Wounds and Injuries
Fondaparinux
Nadroparin
PENTA
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014